Physician profile
Thomas E Wallace
NPI 1306882725
$9,937.56
in general payments reported to CMS, 2019-2025
37 companies · $2,332 in 2025
The $2,332 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,645 · 2020: $133 · 2022: $606 · 2023: $1,973 · 2024: $3,249 · 2025: $2,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,383 · Travel and Lodging: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,383.42 |
| Travel and Lodging | $1,169.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,261.62 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $1,191.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Intuitive Surgical, INC. | $1,169.93 | 2024 | |
| Abbvie INC. | $891.99 | 2019-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $846.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $745.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $604.56 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $583.21 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.59 | 2019-2025 | Synjardy, Jardiance, Stiolto Respimat |
| Astellas Pharma US INC | $311.32 | 2019-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $242.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $238.06 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $195.27 | 2019-2024 | Xarelto |
| Dexcom, INC. | $176.10 | 2022-2025 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $145.59 | 2022-2024 | Crysvita |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.